2. Protein Tyrosine Kinase/RTK
  3. VEGFR
  4. KLTWQELYQLKYKGI

KLTWQELYQLKYKGI is a VEGF mimetic peptide designed based on the VEGF helix sequence 17-25, with the ability to activate VEGF receptors and exert pro-angiogenic biological activity. KLTWQELYQLKYKGI effectively promotes the attachment, spreading and proliferation of human umbilical vein endothelial cells. KLTWQELYQLKYKGI enhances the proliferation, migration and osteogenic differentiation of bone marrow stromal cells (BMSCs). KLTWQELYQLKYKGI synergistically accelerates angiogenesis and bone regeneration in rat cranial defect models. KLTWQELYQLKYKGI can be used for the research of brain tissue engineering and traumatic brain injury repair and biomaterials for bone tissue engineering and bone repair.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

KLTWQELYQLKYKGI

KLTWQELYQLKYKGI Chemical Structure

CAS No. : 917760-16-8

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

KLTWQELYQLKYKGI Related Antibodies

Top Publications Citing Use of Products

View All VEGFR Isoform Specific Products:

View All Isoforms
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

KLTWQELYQLKYKGI is a VEGF mimetic peptide designed based on the VEGF helix sequence 17-25, with the ability to activate VEGF receptors and exert pro-angiogenic biological activity. KLTWQELYQLKYKGI effectively promotes the attachment, spreading and proliferation of human umbilical vein endothelial cells. KLTWQELYQLKYKGI enhances the proliferation, migration and osteogenic differentiation of bone marrow stromal cells (BMSCs). KLTWQELYQLKYKGI synergistically accelerates angiogenesis and bone regeneration in rat cranial defect models. KLTWQELYQLKYKGI can be used for the research of brain tissue engineering and traumatic brain injury repair and biomaterials for bone tissue engineering and bone repair[1][2].

In Vitro

KLTWQELYQLKYKGI (7 d) upregulates the mRNA expression of VEGF, PECAW, and vWF and increases ALP activity and ALP mRNA expression in HUVECs[2].
KLTWQELYQLKYKGI (8 h) promotes the formation of capillary-like structures by HUVECs on Matrigel[2].
KLTWQELYQLKYKGI (5 mg/mL in hydrogel, 5-7 d) enhances the proliferation and migration of BMSCs[2].
KLTWQELYQLKYKGI (14 d) increases calcium deposition and upregulates the mRNA expression of Runx2, BMP-2, and Col 1α in BMSCs[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

KLTWQELYQLKYKGI Related Antibodies
In Vivo

KLTWQELYQLKYKGI (immobilized on HA hydrogel, implanted into lesion cavity of traumatic brain injury (TBI) model in rats, once, 4 weeks) enables HA-KLT hydrogel to well fill the irregular brain lesion cavity and forms a tight connection and permissive interface with host brain tissue[1].
KLTWQELYQLKYKGI (5 mg/mL in gelatin-based blue-light-curable hydrogel, injected into cranial defects and cured with blue light for 2 min, 2 weeks) significantly enhances angiogenesis in the cranial defect area of rats[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Traumatic brain injury (TBI) model in Sprague-Dawley (SD) rats (180-220 g, male)[1]
Dosage: Immobilized on HA hydrogel
Administration: Implanted into lesion cavity of traumatic brain injury (TBI) model in rats, once, 4 weeks
Result: Enabled HA-KLT hydrogel to well fill the irregular brain lesion cavity.
Formed a tight connection and permissive interface with host brain tissue (partially merged).
Showed no macroscopic inflammation or toxicity at the injury site.
Increased the number of newly formed microvessels in the lesion site.
Upregulated the expression of endoglin/CD105 (a specific marker of neoformed blood vessels) in rat brain injury tissue.
Animal Model: Sprague-Dawley (SD) rats (6-8 weeks old, weighing approximately 200 g)[2]
Dosage: 5 mg/mL in gelatin-based blue-light-curable hydrogel
Administration: Injected into cranial defects and cured with blue light for 2 min, 2 weeks
Result: Achieved significantly enhanced angiogenesis in the cranial defect area.
Promoted bone regeneration in the cranial defect of SD rats.
Molecular Weight

1911.25

Formula

C92H143N21O23
CAS No.
Appearance

Solid

Color

White to off-white

Sequence

Lys-Leu-Thr-Trp-Gln-Glu-Leu-Tyr-Gln-Leu-Lys-Tyr-Lys-Gly-Ile
Sequence Shortening

KLTWQELYQLKYKGI
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (52.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.5232 mL 2.6161 mL 5.2322 mL
5 mM 0.1046 mL 0.5232 mL 1.0464 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.89%

SDS (252 KB)

COA (245 KB) LCMS (88 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 0.5232 mL 2.6161 mL 5.2322 mL 13.0804 mL
5 mM 0.1046 mL 0.5232 mL 1.0464 mL 2.6161 mL
10 mM 0.0523 mL 0.2616 mL 0.5232 mL 1.3080 mL
15 mM 0.0349 mL 0.1744 mL 0.3488 mL 0.8720 mL
20 mM 0.0262 mL 0.1308 mL 0.2616 mL 0.6540 mL
25 mM 0.0209 mL 0.1046 mL 0.2093 mL 0.5232 mL
30 mM 0.0174 mL 0.0872 mL 0.1744 mL 0.4360 mL
40 mM 0.0131 mL 0.0654 mL 0.1308 mL 0.3270 mL
50 mM 0.0105 mL 0.0523 mL 0.1046 mL 0.2616 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

KLTWQELYQLKYKGI Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

KLTWQELYQLKYKGI917760-16-8VEGFRVascular endothelial growth factor receptorVEGF mimicking peptideVEGF receptororalproangiogenic peptideInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
KLTWQELYQLKYKGI
Cat. No.:
HY-P5558
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.